We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

30 hedge funds and large institutions have $7.76M invested in Outlook Therapeutics in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more capital invested

Capital invested by funds: $2.79M → $7.76M (+$4.97M)

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

11% more funds holding

Funds holding: 27 → 30 (+3)

0.08% more ownership

Funds ownership: 0.15% → 0.23% (+0.08%)

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
9
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.73M
2
Millennium Management
Millennium Management
New York
+$189K
3
VF
Virtu Financial
New York
+$94.2K
4
Citadel Advisors
Citadel Advisors
Florida
+$91.3K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$65.4K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$54.4K
2
Goldman Sachs
Goldman Sachs
New York
-$32.9K
3
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$24.3K
4
RJFSA
Raymond James Financial Services Advisors
Florida
-$22K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$19K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.03M +$1.73M +82,650 +244%
LA
2
LVW Advisors
New York
$2.27M – – –
Jacobs Levy Equity Management
3
Jacobs Levy Equity Management
New Jersey
$360K -$19K -908 -6%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$349K +$65.4K +3,128 +30%
Millennium Management
5
Millennium Management
New York
$235K +$189K +9,030 New
Two Sigma Investments
6
Two Sigma Investments
New York
$231K +$62.5K +2,990 +51%
Two Sigma Advisers
7
Two Sigma Advisers
New York
$187K -$4.39K -210 -3%
VF
8
Virtu Financial
New York
$144K +$94.2K +4,506 +433%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$135K +$55K +2,633 +104%
Northern Trust
10
Northern Trust
Illinois
$123K -$7K -335 -7%
Citadel Advisors
11
Citadel Advisors
Florida
$114K +$91.3K +4,371 New
Osaic Holdings
12
Osaic Holdings
Arizona
$89K -$8.53K -408 -11%
Capstone Investment Advisors
13
Capstone Investment Advisors
New York
$73K +$58.8K +2,814 New
Renaissance Technologies
14
Renaissance Technologies
New York
$71K -$54.4K -2,605 -49%
Goldman Sachs
15
Goldman Sachs
New York
$60K -$32.9K -1,575 -41%
ECM
16
ExodusPoint Capital Management
New York
$49K +$39.3K +1,880 New
Arrowstreet Capital
17
Arrowstreet Capital
Massachusetts
$35K -$24.3K -1,165 -46%
Morgan Stanley
18
Morgan Stanley
New York
$33K +$26.1K +1,250 New
Creative Planning
19
Creative Planning
Kansas
$31K – – –
Qube Research & Technologies (QRT)
20
Qube Research & Technologies (QRT)
United Kingdom
$30K +$24.4K +1,169 New
NA
21
NewEdge Advisors
Louisiana
$26K +$20.9K +1,000 New
RIA
22
Realta Investment Advisors
Delaware
$20K +$5.22K +250 +50%
MFGP
23
Marshall Financial Group (Pennsylvania)
Pennsylvania
$15K – – –
Bank of America
24
Bank of America
North Carolina
$13K +$7.11K +340 +213%
CB
25
CNB Bank
Pennsylvania
$13K +$10.4K +500 New
1
2

OTLK Hedge Fund Activity: Q4 2020 in Review

30 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q4 2020, worth a combined $7.76M — up 178% from $2.79M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OTLK positions and 4 closed out — a net gain of 5 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.73M. The largest seller was Renaissance Technologies, cutting an estimated $54.4K.

  • 30 institutional investors held Outlook Therapeutics (OTLK) as of Q4 2020, up from 27 in Q3 2020.
  • Funds reported $7.76M of Outlook Therapeutics stock for Q4 2020, up 178% quarter-over-quarter.
  • 9 funds opened new Outlook Therapeutics positions in Q4 2020 and 4 closed out, a net change of +5 holders.
  • The largest Outlook Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $1.73M added.
  • The largest Outlook Therapeutics seller in Q4 2020 was Renaissance Technologies, an estimated $54.4K sold.

Based on aggregated 13F filings for Q4 2020.